Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.49 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.42 |
| ▸ | REN known ✓ | P00797 | 1/20 | 0.42 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.40 |
| ▸ | HSD11B1 known ✓ | P28845 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL114920 | 0.98 | BTK (0.51) | BTKEPHX2GAACTSKEPHX1 | |
| Hydrochloric Acid SCHEMBL2280156 | 0.94 | EPHX2 (0.52) | BTKEPHX2GAACTSKEPHX1 | |
| Acetic Acid SCHEMBL1576649 | 0.93 | BTK (0.51) | BTKEPHX2GAACTSKEPHX1 | |
| SCHEMBL5390787 | 0.91 | BTK (0.53) | BTKEPHX2GAACTSKEPHX1 | |
| SCHEMBL1710195 | 0.91 | BTK (0.53) | BTKEPHX2GAACTSKEPHX1 | |
| SCHEMBL5376383 | 0.91 | BTK (0.53) | BTKEPHX2GAACTSKEPHX1 | |
| SCHEMBL5390795 | 0.91 | BTK (0.53) | BTKEPHX2GAACTSKEPHX1 | |
| SCHEMBL554933 | 0.91 | EPHX2 (0.49) | BTKEPHX2GAACTSKEPHX1 | |
| Trifluoroacetic Acid SCHEMBL27829992 | 0.88 | BTK (0.48) | BTKEPHX2GAACTSKEPHX1 | |
| Hydrochloric Acid SCHEMBL31088698 | 0.86 | BTK (0.49) | BTKEPHX2GAACTSKEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 356 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637461-B2 | Compounds for the activation of AMPK | PFIZER INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12534465-B2 | 5H-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof | SUTRO BIOPHARMA, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-12479834-B2 | Phenol compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-11-25 | — | — | US | disclosed |
| US-12421239-B2 | — | — | 2025-09-23 | — | — | US | disclosed |
| US-20250270180-A1 | MEK INHIBITORS AND THERAPEUTIC USES THEREOF | IMMUNEERING CORPORATION | 2025-08-28 | — | — | US | disclosed |
| US-12351566-B2 | MEK inhibitors and therapeutic uses thereof | IMMUNEERING CORPORATION (US) | 2025-07-08 | — | — | US | disclosed |
| EP-4577531-A1 | NOVEL SUBSTITUTED 2-CARBONYL-BENZOTHIOPHENE-6- CARBOXYLIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2025-07-02 | — | — | EP | disclosed |
| WO-2025096771-A1 | MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PROGENTOS THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| US-20250115581-A1 | SUBSTITUTED PIPERIDINES AS CK1A DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2025-04-10 | — | — | US | disclosed |
| EP-1932837-A1 | BICYCLO HETEROCYCLIC COMPOUND HAVING ANTIFUNGAL ACTION | Daiichi Sankyo Company, Limited (JP) | 2008-06-18 | — | — | EP | disclosed |
| US-20080096860-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| EP-1809624-A1 | PYRIMIDINE SULPHONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006024823-A1 | PYRIMIDINE SULPHONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | disclosed |
| US-5849780-A | 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present | SANOFI (FR) | 1998-12-15 | — | — | US | disclosed |
| US-5728723-A | ANTIDIURETIC AND OXYTOCIN RECEPTORS | SANOFI (FR) | 1998-03-17 | — | — | US | disclosed |
| US-5726322-A | 1-benzenesulfonyl-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present | SANOFI (FR) | 1998-03-10 | — | — | US | disclosed |
| US-5686624-A | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present | SANOFI (FR) | 1997-11-11 | — | — | US | disclosed |
| US-5663431-A | CHEMICAL INTERMEDIATES | SANOFI (FR) | 1997-09-02 | — | — | US | disclosed |
| CN-1107467-A | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present | SANOFI SA (FR) | 1995-08-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115581-A1 | SUBSTITUTED PIPERIDINES AS CK1A DEGRADERS | CKS1B, CSNK1A1, CKS2 | GAA 667/4885CA2 1356/4885REN 2527/4885 |
| US-20250270180-A1 | MEK INHIBITORS AND THERAPEUTIC USES THEREOF | BRAF, NRAS, RAF1 | GAA 2231/4885CA2 4236/4885REN 543/4885 |
| US-12421239-B2 | — | FCGRT, DPYD, CD2BP2 | GAA 1361/4885CA2 3433/4885REN 3319/4885 |
| US-12637461-B2 | Compounds for the activation of AMPK | PRKAG1, PRKAB1, PRKAA1 | GAA 3019/4885CA2 1495/4885REN 401/4885 |
| US-12534465-B2 | 5H-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof | CD22, FCGR3B, FCGR2A | GAA 3417/4885CA2 961/4885REN 237/4885 |
| US-20080096860-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | CXCR1, CCR5, ACKR3 | GAA 1910/4885CA2 3317/4885REN 384/4885 |
| US-12351566-B2 | MEK inhibitors and therapeutic uses thereof | BRAF, NRAS, RAF1 | GAA 2231/4885CA2 4236/4885REN 543/4885 |
| US-12479834-B2 | Phenol compound or salt thereof | REN, MLX, MYB | GAA 2659/4885CA2 612/4885REN 1/4885 |
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PDGFRB, PDGFRA, PDGFA | GAA 1256/4885CA2 4373/4885REN 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.